INTRODUCTION
Ebola virus (EBOV) derived its name from the Ebola River in Democratic Republic of Congo (DRC) (formerly Zaire) where the first Ebola virus disease (EVD) outbreak was identified in 1976 [1] . Historically, outbreaks of EVD have been confined to a single country and have investigation, the spread of EBOV occurred rapidly because of a number of factors including funeral and burial practices for decedents [3, 4] . The scope and severity of the EVD outbreak underscore the urgent need for development and evaluation of affordable therapeutic and prophylactic agents that can be made available for at-risk populations across Africa. Over the past 17 months, the West Africa EVD outbreak has provided an important opportunity to consider use of and evaluate several therapeutic and prophylactic agents (e.g., vaccines) to determine their safety and efficacy [5, 6] .
Review Methods
For this review, we considered published and unpublished reports related to EBOV and were inspected and reviewed to identify up-to-date information relevant to Ebola.
Studies were included in the proposed literature review if they (1) were published in the English language; (2) were full-text articles; (3) focused on Ebola virus virology, epidemiology, diagnosis, treatment and clinical trials on vaccines and treatment; (4) were published between 1993 and 2015; (5) were published in peer-reviewed journals. We excluded studies if they (1) were not full-text articles; (2) were published before 1993; (3) were published in non-peer-reviewed journals. We identified 156 studies for inclusion in this review. Seventy-one studies focused on epidemiology, public health Marburgvirus are the two genera of filoviruses that have been identified to cause severe disease in humans [7, 8] . Within the genus Spain [12] . Cuevavirus has not been grown in cell culture, and its pathogenic potential for humans remains unknown. To date, a single species (Lloviu cuevavirus) has been approved by the International Committee on Taxonomy of Viruses (ICTV) [9] .
Fig. 1 Flowchart for the literature search
The current West Africa outbreak is caused
by Zaire ebolavirus, which shows 97% identity to EBOV strains from the DRC and Gabon [13] . The surface GP is responsible for the attachment to the cellular receptor and viral entry. L protein is the RNA-dependent RNA polymerase [15] [16] [17] [18] [19] [20] .
Early reports suggest that the EBOV variant of the 2014-2015 West Africa outbreak accumulated mutations that may have an impact on the performance of certain diagnostic tests or even on the efficacy of several experimental treatments. Gire et al.
analyzed the genetic sequence of 99 EBOV genomes from 78 patients in the four most affected countries of the West African region [16] . They found significant rates of genomic variation in EBOV in the current outbreak when compared with the EBOV genomic sequence in the 2004 Ebola outbreak in the DRC. Although the impact of these mutations on the diagnostic tests and experimental therapeutics has not yet been proven, some mutations exist in viral genes that are targeted by primers of some reverse transcription-polymerase chain reaction (RT-PCR) protocols [21] , as well as mutations in the binding sites of target proteins of some experimental treatments such as anti-GP monoclonal antibodies [22] . In 2015, Hoenen and colleagues studied full-length sequences of two clusters of EBOV imported from Mali and found that the gene sequence of EBOV has remained stable during the current Ebola outbreak [23] .
Epidemiology and Outbreaks
Ebola viruses have been responsible for 33 outbreaks in six African countries [2] . Historically, the outbreaks have affected hundreds of individuals where effective control of outbreaks was achieved primarily through isolation of cases and contact tracing.
However, from 2000, EVD outbreaks have been recognized almost every year with substantial variation in morbidity and case-fatality rates ranging from 24% to 81% [24] . High case-fatality rates have been associated with the Zaire and Sudan subtypes [25] . In the ongoing Ebola outbreak, the overall case-fatality rate has been estimated to be approximately 41% for West Africa and other affected countries [26] . Most recently, although the number of cases has declined substantially ( Fig. 2) , EVD cases continue to be reported (please see the supplemental table for details) in Guinea, Liberia and Sierra Leone with WHO Ebola situation reports noting weekly cases in July 2015 [27] . In July 2015, situation report statistics from the WHO suggest that the greatest current burden of EVD is found in Guinea (n = 43) and Sierra Leone (n = 31).
Liberia reported the lowest EVD case number (n = 3) in the week of 29 June through 5 July [27] .
The search for the natural reservoir host of EBOV has been a matter of investigation during the last decades. There is mounting evidence that a number of mammal species may harbor and transmit the virus. Several bat species (i.e., Epomops franqueti, Hypsignathus monstrosus and Myonycteris torquata) have been found to carry filoviruses [28] [29] [30] [31] [32] [33] [34] [35] 
TRANSMISSION AND CLINICAL SYNDROME
Humans may acquire the disease by close contact with biological fluids from infected animals or patients. During the acute phase of illness, EBOV has been detected in a variety of body fluids including breast milk, saliva, semen, stool, sweat, tears and urine [36] [37] [38] [39] [40] .
Nevertheless, the EBOV viral load by organ has not been extensively studied although EBOV has been detected in the semen of survivors up to 3 months following onset of symptoms [41, 42] . EBOV has been isolated from urine and from aqueous humor samples 9 days and 9 weeks, respectively, after the virus was cleared from plasma [37, 43] .
The clinical presentation of the current West Africa outbreak is, in general, similar to that described in prior EBOV epidemics. The incubation period for person-to-person transmitted EVD typically ranges from 8 to [53] . No evidence suggests that pregnant women are more susceptible to EBOV infection than the general population. However, they might be at increased risk of severe illness and fetal loss. Although no large series are available, the fetal outcome is generally fatal.
Immune suppression and a systemic inflammatory response due to the release of cytokines and other proinflammatory mediators lead to the impairment of vascular, coagulation and immune systems [54] . This can result in multiorgan failure and shock resembling a septic shock syndrome. Massive fluid losses due to intense vomiting and profuse diarrhea can result in dehydration and hypovolemic shock [49] . Severe lymphopenia as well as significant deterioration of renal and liver functions, which may be reflected in high blood urea nitrogen, serum creatinine and hepatic enzymes (i.e., aminotransferases and alkaline phosphatase), can occur [21, 55, 56] .
Since EBOV is a contagious pathogen, the WHO and Centers for Disease Control (CDC) have issued recommendations for proper handling of biological specimens from suspected cases of EVD [57, 58] . Extreme caution should take place at all stages (i.e., specimen acquisition, transport, processing and testing) of specimen processing, and appropriate biosafety laboratory procedures must be used when handling biological specimens from patients with suspected EVD. 
DIAGNOSIS OF EBOLA VIRUS DISEASE

Favipiravir (T-705)
Favipirarvir is a nucleotide analog and viral RNA polymerase inhibitor with a wide range of antiviral effects against numerous negative-or positive-strand RNA viruses [83] [84] [85] [86] [87] [88] . Initially, favipiravir was developed to treat influenza viruses, and a phase III clinical trial was completed in which favipiravir was tested on several thousands of people and proven to be safe and effective [84] . Recently, favipiravir has also shown efficacy against EBOV in vitro and in vivo in a mouse model [89] . Two independent animal studies have demonstrated that treatment with favipiravir resulted in rapid viral clearance and led to survival of all animals infected with EBOV through intranasal inoculation [89, 90] . A phase II clinical trial to evaluate the efficacy of favipiravir against EBOV in 225 patients with an 
Other Small Molecules and Compounds
There are a number of known agents and newly identified compounds that have shown anti-EBOV activity. For example, Compound 7 is a benzodiazepine derivative that also prevents EBOV entry into the host cells [101] .
Preliminary analysis suggests that Compound 7 binds near a hydrophobic pocket near the EBOV GP1 and GP2 interface. Analysis of this compound suggests that it may have activity against several filoviruses including EBOV [101] .
No animal or human trials have been reported to date.
NSC 62914 is a small molecule, which has an antioxidant property, and was found to inhibit many viruses, including EBOV, Lassa virus, Venezuelan equine encephalitis virus and Rift Valley fever virus [102] . This compound, a reactive oxygen species, has shown in vitro activity against EBOV as well as some evidence in the EBOV mouse model for protection against lethal EBOV infection at a treatment dose of 2 mg/kg/injection (higher doses did not improve survival in the mouse model). Further studies of this or related compounds in mouse and other animal models may be warranted to elucidate their role in the treatment of EBOV and other filovirus infections.
Of additional interest are compounds that have been proven to be effective in preventing the entry of filoviruses, including EBOV, into host cells [103] . LJ-001 binds to lipid membranes and prevents virus-cell fusion across a wide range of viruses. Additional research will be needed to understand how such compounds can be optimally formulated to maximize both the safety and pharmacologic activity in vivo. FGI-103, FGI-104, and FGI-106 are a group of broad-spectrum antiviral agents that inhibit viral replication in a dose-dependent manner among multiple and genetically distinct viruses including EBOV, bunyaviruses, dengue virus, HIV and hepatitis C virus [104] . Using a mouse model, Aman et al. found that FGI-106 yields a protection after a challenge with a lethal dose of EBOV. Aman and colleagues showed that protection was also found when FGI-106 was administered in a prophylactic fashion. In related studies, FGI-103 and FGI-104 are also small molecules that inhibit filovirus infection and are found to protect EBOV-or Marburg-infected mice, although their mechanism of actions are unclear [105, 106] . Spain shed some light on the issue of using experimental therapeutics including CP [121] .
The infected nurse had received convalescent sera from two survivors of EVD, high-dose favipiravir and other supportive care treatment.
On the 10th day of clinical disease, the nurse developed clinical signs and symptoms suggestive of post-transfusion acute lung injury, which was managed conservatively without the need of supportive mechanical ventilation.
Although purified IgG can lower these risks, lot-to-lot variation remains a potential problem.
Previous experience also highlights the risk of antibody-dependent enhancement of EBOV infection [122] . NHPs (usually rhesus and cynomolgus macaque) can be infected with non-adapted strains and best mimic disease progression in humans, and therefore they are considered the ''reference'' animal model for vaccine studies [147] . Differences can also be found in the EBOV antigens included in the vaccines. promising in providing more timely and accurate EBOV detection, there will be a need for additional research to study optimal strategies for deploying these diagnostics to locations where testing is most needed. In the near future, there is a substantial likelihood that one or more drugs and vaccines will be approved for use in the treatment and prevention of EVD. The availability of new agents for prevention, acute therapy and post-exposure prophylaxis will require additional research to identify and reduce 
